Here are the 424B prospectus supplements from Baird Medical Investment Holdings Ltd Warrant (BDMDW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow BDMDW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BDMDW filings page.
Baird Medical Investment Holdings Ltd. (BDMD) is offering a US$4,347,826 senior 8% original issue discount convertible promissory note, ordinary shares issuable upon conversion, and up to 110,070 commitment shares. It estimates net proceeds of approximately US$3.7 million after offering expenses for general corporate purposes. The note has a 12-month term and accrues no interest unless an event of default occurs.
The conversion price is the lower of a $0.9842 fixed price and, subject to specified events, an alternative price based on 92% of the lowest daily VWAP over the prior seven trading days, or 85% upon an event of default; the floor is $0.158. Up to 27,517,886 ordinary shares may be issued upon conversion at the floor, subject to a 9.99% limit on the holder's and attribution parties' collective beneficial ownership. BDMD reported approximately $22.5 million in fiscal 2025 revenue, down 39.2% from approximately $37.0 million in fiscal 2024, and a net loss of approximately $27.5 million. It also identified material weaknesses in internal controls over financial reporting as of December 31, 2025.